
Adaptimmune Therapeutics plc
- Jurisdiction
United Kingdom - LEI
549300UUNWK8TRT5EW12 - ISIN
US00653A1079 (ADAP )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
2
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
2
/ 7
Profile
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. Read full profile
Stock price
Fundamentals
- Net revenue
€55.84M - Gross margin
94.8% - EBIT
-€140.90M - EBIT margin
-252.3% - Net income
-€145.65M - Net margin
-260.8%
Statement period: - (published )
Estimates
Fiscal Year | Net revenue | Net income |
---|---|---|
|
| |
|
| |
|
|
Dividends
No dividend payouts
Insider Transactions
Name | Title | Transaction Date | Shares | Price | Value |
---|---|---|---|---|---|
Wood Gavin | Chief Financial Officer |
|
|
|
|
Bertrand William C JR | Chief Operating Officer |
|
|
|
|
Behbahani Ali | N/A |
|
|
|
|
EcoR1 Capital, LLC | N/A |
|
|
|
|
Earnings Calls
Latest earnings call: May 15, 2024
Investor transactions
Name | Shares | Value | Last change | Change type |
---|---|---|---|---|
Peter Brown |
|
|
|
Sell |